HLX22 plus Enhertu for HR+, HER2-low breast cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older.
- Diagnosed with advanced or metastatic breast cancer that is HER2-low and hormone receptor positive.
- Cancer has not been treated with any HER2-targeted therapy before.
- At least one measurable tumor that is not only in the bone.
- Good overall health (ECOG 0 or 1) and expected to live at least 6 months.
- No history of other cancer in the last 3 years (except certain skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
This Phase 2 trial studies trastuzumab deruxtecan (T‑DXd) as a first treatment for people with HER2‑low, triple‑negative breast cancer that has spread or returned and cannot be fully removed by surgery. It aims to shrink tumors and control the disease while checking safety and side effects.
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
This trial tests a combination of a targeted drug (Enhertu) with precise radiation (SRS) for people whose HER2-positive breast cancer has spread to the brain. It aims to see if this combo is safe and effective for treating brain metastases.
Hear when a new HER2-low Hormone Receptor Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.